kinase inhibitor engineering

ABLi Therapeutics, Inc. develops innovative treatments for Parkinson's disease and other neurodegenerative disorders by targeting non-receptor Abelson Tyrosine Kinases (Abl kinases or c-Abl) with small molecule inhibitors. Its proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) drug innovation engine uses clinically validated kinase inhibitor data to design novel product candidates with enhanced brain penetration, potentially higher potency and improved safety.

Read more

drug innovation/developmentsmall molecule inhibitor development